Achaogen Stock

AKAOQ

US0044491043

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	+278.79%

12/06/20	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
29/05/20	Achaogen, Inc. Went Out of Business	CI

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.

Employees

Sector

More about the company

Market Cap	639K 572K 526K 477K 891K 60.65M 908K 6.28M 2.52M 31.91M 2.4M 2.35M 101M	P/E 2017	-3.39x	P/E 2018	-0.29x
Enterprise Value	19.47M 17.43M 16.04M 14.53M 27.16M 1.85B 27.67M 191M 76.77M 972M 73.06M 71.5M 3.07B	EV / Sales 2017	28x	EV / Sales 2018	8.66x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

12/06/20	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
29/05/20	Achaogen, Inc. Went Out of Business	CI
29/05/20	First Amended Joint Liquidation Plan and Disclosure Statement Approved for Achaogen, Inc.	CI
22/04/20	First Amended Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
21/04/20	Disclosure Statement Approved on Interim Basis for Achaogen, Inc.	CI
30/03/20	Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
09/01/20	Motion for Asset Sale Approved for Achaogen, Inc.	CI
29/12/19	Motion for Asset Sale Filed by Achaogen, Inc.	CI
24/09/19	Final DIP Financing Approved for Achaogen, Inc.	CI
29/08/19	Motion for Exclusivity Period Extension Approved For Achaogen, Inc.	CI
13/08/19	First Motion for Exclusivity Period Extension Filed by Achaogen, Inc.	CI
30/07/19	Achaogen, Inc. Announces Management Changes	CI
23/07/19	Motion for Asset Sale Approved for Achaogen, Inc.	CI

	2017	2018
Net sales	11.18M 10.01M 9.21M 8.34M 15.59M 1.06B 15.88M 110M 44.07M 558M 41.94M 41.05M 1.76B	8.73M 7.82M 7.19M 6.51M 12.18M 829M 12.41M 85.74M 34.42M 436M 32.76M 32.06M 1.37B
Net income	-126M -113M -103M -93.77M -175M -11.93B -179M -1.23B -495M -6.27B -471M -461M -19.79B	-187M -167M -154M -139M -260M -17.71B -265M -1.83B -736M -9.32B -700M -685M -29.38B
Net Debt	-143M -128M -118M -107M -199M -13.56B -203M -1.4B -563M -7.13B -536M -525M -22.5B	18.83M 16.86M 15.51M 14.05M 26.27M 1.79B 26.76M 185M 74.25M 940M 70.66M 69.16M 2.97B

Achaogen Stock

Stocks

AKAOQ

US0044491043

Valuation: Achaogen

Latest news: Achaogen

Financials

Company Profile